Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

8.52
+0.22002.65%
Volume:1.39M
Turnover:11.73M
Market Cap:495.34M
PE:-3.46
High:8.67
Open:8.32
Low:8.26
Close:8.30
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:45.54M
Volume Ratio:0.54
T/O Rate:3.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:2.01
PE(LYR):-3.77

Loading ...

Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program

Reuters
·
May 29

Capricor names Michael Maurer chief commercial officer

Reuters
·
May 29

Capricor Therapeutics files Form 3 for Chief Commercial Officer Michael T. Maurer

Reuters
·
May 29

A Look At Capricor Therapeutics (CAPR) Valuation After Deramiocel Launch Delay And Milestone Cut

Simply Wall St.
·
May 25

Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program

Reuters
·
May 21

Capricor Faces Revenue Risk as Dependence on Nippon Shinyaku Puts Deramiocel Commercialization in Jeopardy

TIPRANKS
·
May 15

Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)

TIPRANKS
·
May 15

Assessing Capricor Therapeutics (CAPR) Valuation After Strong Multi Year Gains And Recent Share Price Pullback

Simply Wall St.
·
May 14

Capricor Therapeutics Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
May 13

BRIEF-Capricor Therapeutics Reports First Quarter 2026 Financial Results

Reuters
·
May 13

Capricor Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Capricor Therapeutics Q1 Loss Widens

MT Newswires Live
·
May 13

Capricor Q1 FY26 net loss widens to $33.9 million; revenue remains no revenue

Reuters
·
May 13

Capricor Therapeutics options imply 9.4% move in share price post-earnings

TIPRANKS
·
May 13

Capricor Therapeutics Q1 EPS $(0.59) Misses $(0.50) Estimate

Benzinga Earnings
·
May 13

Capricor Therapeutics Inc - No Revenue Recognized for Q1 2026 or Q1 2025

THOMSON REUTERS
·
May 13

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 13

Capricor Therapeutics: Available Cash, Cash Equivalents, Marketable Securities Sufficient to Cover Expenses & Capital Requirements Through Q4 2027

THOMSON REUTERS
·
May 13

Analysts Offer Insights on Healthcare Companies: ImageneBio (IMA) and Capricor Therapeutics (CAPR)

TIPRANKS
·
May 11

Capricor files suit against NS Pharma over Deramiocel distribution deal

TIPRANKS
·
May 09